[March 07, 2018] |
|
Global Biologics Development and Manufacturing Testing Technologies and Markets Research Report 2018 - ResearchAndMarkets.com
The "Biologics
Development and Manufacturing Testing: Technologies and Global Markets"
report has been added to ResearchAndMarkets.com's
offering.
The scope of this study encompasses all aspects of biological safety
testing used for characterization and release of biopharmaceutical,
veterinary and medical diagnostics products. This research analyzes each
market and its applications, regulatory environments, technology, market
projections, and market share. Technological issues discussed in the
report include the latest trends and developments.
Report Includes:
-
An overview of the global market for biological safety testing and
related technologies.
-
Analyses of global market trends, with data from 2016 and 2017, and
projections of compound annual growth rates (CAGRs) through 2022.
-
Discussion of the latest market trends, regulatory environments,
market projections, and market share.
-
A look at future of biological patents and biosimilars along with
biologics patents by year.
-
Company profiles of major players in the industry, including Charles
River Laboratories, WuXi AppTec, SGS SA, Thermo Fisher Scientific and
Lonza Group.
Summary of Key Insights:
-
The decline in in vivo esting due to development of newer in vitro
toxicology and efficacy tests
-
Public opposition to in vivo testing based upon ethical considerations
-
The anticipated growth for in vitro testing, especially due to the
cell-based segment
-
Development of new cell lines that express specific biomarkers for
disease states and comparative diagnostics
-
The growth of personalized medicines based upon the advancement of
autologous cell replacement or transfusion- based (i.e., CAR/T)
therapies and elucidation of mechanisms of disease using in vitro
models
-
Finally, the increasing number of brand name biologics coming off
patent protection will result in a growing market for biosimilars or
generic biologics-many of which will be manufactured overseas by
contract manufacturing organizations (or CMO's) and will drive the
need for increased bioequivalence testing in many markets (especially
in Europe and Asia-Pacific )and will serve to increase the overall
percentage of outsourced biological safety testing by large
pharmaceutical and biopharmaceutical companies.
Key Topics Covered:
1. Introduction
2. Summary and Highlights
3. Overview
4. Market Breakdown by Test Objective
5. Market Breakdown by Test Application
6. Market Breakdown by Test Technology
7. Market Breakdown by Region
8. Patent Review/ New Developments
9. Analysis of Market Opportunities
10. Company Profiles
-
Admecell Inc.
-
American Type Culture Collection (ATCC)
-
Avance Biosciences
-
Bioreliance
-
BSL Bioservice
-
Catalent Inc.
-
Charles River Laboratories
-
Covance
-
Cytovance Biologics
-
EMD Millipore
-
Eurofins Scientific
-
Intertek (News - Alert) Group PLC
-
Lonza Group
-
Pharmaceutical Product Development LLC (PPD)
-
Sartorius AG
-
Sekisui XenoTech LLC
-
Selexis SA
-
SGS S.A. Corp.
-
Sigma-Aldrich
-
Toxikon Corp.
-
WuXi Apptec
For more information about this report visit https://www.researchandmarkets.com/research/4jsgrz/global_biologics?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20180307006229/en/
[ Back To TMCnet.com's Homepage ]
|